U.S. market Closed. Opens in 16 hours 9 minutes

LGVN | Longeveron Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 3.11 - 3.75
52 Week Range 0.7707 - 36.50
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 6,101,320
Average Volume 10,114,397
Shares Outstanding 9,600,914
Market Cap 31,202,971
Sector Healthcare
Industry Biotechnology
IPO Date 2021-02-12
Valuation
Profitability
Growth
Health
P/E Ratio -0.34
Forward P/E Ratio N/A
EPS -9.60
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 23
Country USA
Website LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
*Chart delayed
Analyzing fundamentals for LGVN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see LGVN Fundamentals page.

Watching at LGVN technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on LGVN Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙